⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820114 | 0.69 | — | — | |
| SCHEMBL19742932 | 0.69 | — | — | |
| SCHEMBL2382157 | 0.63 | — | — | |
| SCHEMBL18042438 | 0.63 | — | — | |
| SCHEMBL6502350 | 0.58 | — | — | |
| SCHEMBL4947249 | 0.58 | — | — | |
| SCHEMBL5997087 | 0.58 | — | — | |
| SCHEMBL1189666 | 0.58 | — | — | |
| SCHEMBL4537423 | 0.58 | — | — | |
| SCHEMBL35210236 | 0.55 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023043803-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20140256743-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2014-09-11 | — | — | US | disclosed |
| US-8772336-B2 | Cathepsin cysteine protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2014-07-08 | — | — | US | disclosed |
| US-8703277-B2 | Curable resin composition | ASAHI KASEI E-MATERIALS CORPORATION (JP) | 2014-04-22 | — | — | US | disclosed |
| US-20130266779-A1 | CURABLE RESIN COMPOSITION | ASAHI KASEI E-MATERIALS CORPORATION (JP) | 2013-10-10 | — | — | US | disclosed |
| US-20130035312-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBIORS | AXYS PHARMACEUTICALS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
| US-8318748-B2 | Cathepsin cysteine protease inhibitors | Merck, Sharp & Dohme Corp. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20080188529-A1 | N1-(cyanomethyl)-N2-(2,2,2-trifluoro-1-phenylethyl)-L-leucinamide; antiarthritic agent; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2008-08-07 | — | — | US | disclosed |
| US-7375134-B2 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | AXYS PHARMACEUTICALS, INC. (US) | 2008-05-20 | — | — | US | disclosed |
| EP-1394617-B1 | Electrophotographic Photosensitive Member, Process Cartridge and Electrophotographic Apparatus | CANON KK (JP) | 2006-12-13 | — | — | EP | disclosed |
| US-6994941-B2 | comprises bis(2,4-dimethylphenyl)amine as charge transfer compound; improved wear/scratch resistance and stability | CANON KABUSHIKI KAISHA (JP) | 2006-02-07 | — | — | US | disclosed |
| US-20050240023-A1 | N1-(1-cyanocyclopropyl)-4-fluoro-N2-{(1S)-2,2,2-trifluoro-1-[4'-(methylsulfonyl)-1,1'-biphenyl-4-yl]ethyl}-L-leucinamide; osteoporosis and other bone loss disorders | MERCK CANADA INC. (CA) | 2005-10-27 | — | — | US | disclosed |
| US-20050208402-A1 | Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus | CANON KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | US | disclosed |
| US-20050100805-A1 | Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus | CANON KABUSHIKI KAISHA (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1394617-A2 | Electrophotographic Photosensitive Member, Process Cartridge and Electrophotographic Apparatus | CANON KABUSHIKI KAISHA (JP) | 2004-03-03 | — | — | EP | disclosed |